Overview

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, Phase 1 study to determine the mass balance of of GS-5806 following administration of a single, oral dose of radiolabeled [14C]-GS-5806 in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Gilead Sciences